These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 24362783)
1. [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors]. Fiorentino TV; Sesti G G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):15-25. PubMed ID: 24362783 [TBL] [Abstract][Full Text] [Related]
2. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors. Kumar A Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862 [TBL] [Abstract][Full Text] [Related]
3. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors. Boland CL; Degeeter M; Nuzum DS; Tzefos M Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652 [TBL] [Abstract][Full Text] [Related]
6. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Deacon CF; Mannucci E; Ahrén B Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248 [TBL] [Abstract][Full Text] [Related]
7. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis. Dai X; Wang H; Jing Z; Fu P Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140 [TBL] [Abstract][Full Text] [Related]
8. Beyond glycemic control: treating the entire type 2 diabetes disorder. Brunton S Postgrad Med; 2009 Sep; 121(5):68-81. PubMed ID: 19820276 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin. Fass AD; Gershman JA Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Liu Y; Hong T Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534 [TBL] [Abstract][Full Text] [Related]
12. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus. Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538 [TBL] [Abstract][Full Text] [Related]
13. [Drug treatment of type 2 diabetes]. Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675 [TBL] [Abstract][Full Text] [Related]
14. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin. Forst T; Bramlage P Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407 [TBL] [Abstract][Full Text] [Related]
15. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study. Enders D; Kollhorst B; Engel S; Linder R; Verheyen F; Pigeot I J Diabetes Complications; 2016; 30(7):1339-46. PubMed ID: 27245402 [TBL] [Abstract][Full Text] [Related]
16. Weight beneficial treatments for type 2 diabetes. Meneghini LF; Orozco-Beltran D; Khunti K; Caputo S; Damçi T; Liebl A; Ross SA J Clin Endocrinol Metab; 2011 Nov; 96(11):3337-53. PubMed ID: 21900381 [TBL] [Abstract][Full Text] [Related]
17. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Ovalle F Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987 [TBL] [Abstract][Full Text] [Related]
18. Body Weight Considerations in the Management of Type 2 Diabetes. Apovian CM; Okemah J; O'Neil PM Adv Ther; 2019 Jan; 36(1):44-58. PubMed ID: 30465123 [TBL] [Abstract][Full Text] [Related]
19. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials. Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161 [TBL] [Abstract][Full Text] [Related]
20. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication. Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]